Moreover, although selective PDE1B and PDE10A inhibitors have demonstrated preclinical efficacy in ameliorating both positive and negative symptom-like behaviors, clinical translation has encountered challenges, including inadequate CNS penetration, dose-limiting toxicities, and variable target engagement
Biochemistry 28 , 35623568 (1989)
2022 JAMA Internal Medicine meta-analysis: pooling 76 randomised controlled trials, GLP-1 receptor agonist use was associated with a relative risk of 1.37 for biliary disease compared with placebo or other treatments
That means the drink you used to handle easily might now hit harder, sit heavier, and cause gastrointestinal symptoms you never experienced before
So do GLP-1 medications directly cause muscle loss